iNtRON Biotechnology, Inc. (048530.KQ)

KRW 5500.0

(-4.35%)

Revenue Summary of iNtRON Biotechnology, Inc.

iNtRON Biotechnology, Inc.'s latest annual revenue in 2023 was 9.58 Billion KRW , down -31.57% from previous year.
iNtRON Biotechnology, Inc.'s latest quarterly revenue in 2024 Q2 was 1.77 Billion KRW , down -6.92% from previous quarter.
iNtRON Biotechnology, Inc. reported a annual revenue of 14 Billion KRW in annual revenue 2022, down -52.21% from previous year.
iNtRON Biotechnology, Inc. reported a annual revenue of 29.3 Billion KRW in annual revenue 2021, down -35.49% from previous year.
iNtRON Biotechnology, Inc. reported a quarterly revenue of 1.77 Billion KRW for 2024 Q2, down -6.92% from previous quarter.
iNtRON Biotechnology, Inc. reported a quarterly revenue of 9.58 Billion KRW for 2023 FY, down -31.57% from previous quarter.

Annual Revenue Chart of iNtRON Biotechnology, Inc. (2023 - 2012)

Historical Annual Revenue of iNtRON Biotechnology, Inc. (2023 - 2012)

Year	Revenue	Revenue Growth
2023	9.58 Billion KRW	-31.57%
2022	14 Billion KRW	-52.21%
2021	29.3 Billion KRW	-35.49%
2020	45.43 Billion KRW	444.28%
2019	8.34 Billion KRW	-59.45%
2018	20.58 Billion KRW	87.77%
2017	10.96 Billion KRW	7.24%
2016	10.22 Billion KRW	-13.63%
2015	11.83 Billion KRW	0.0%
2012	8.17 Billion KRW	0.0%

Year	Revenue	Revenue Growth
2024 Q1	1.91 Billion KRW	-48.63%
2024 Q2	1.77 Billion KRW	-6.92%
2023 FY	9.58 Billion KRW	-31.57%
2023 Q3	1.67 Billion KRW	-21.24%
2023 Q4	3.71 Billion KRW	122.48%
2023 Q2	2.12 Billion KRW	2.34%
2023 Q1	2.07 Billion KRW	-14.84%
2022 Q3	2.82 Billion KRW	3.52%
2022 FY	14 Billion KRW	-52.21%
2022 Q4	2.43 Billion KRW	-13.93%
2022 Q2	2.73 Billion KRW	-54.53%
2022 Q1	6 Billion KRW	-25.89%
2021 Q1	5.73 Billion KRW	-51.45%
2021 FY	29.3 Billion KRW	-35.49%
2021 Q4	8.1 Billion KRW	5.09%
2021 Q2	7.75 Billion KRW	35.24%
2021 Q3	7.71 Billion KRW	-0.44%
2020 Q3	7 Billion KRW	-70.0%
2020 FY	45.43 Billion KRW	444.28%
2020 Q4	11.8 Billion KRW	68.45%
2020 Q1	3.26 Billion KRW	48.35%
2020 Q2	23.35 Billion KRW	615.23%
2019 FY	8.34 Billion KRW	-59.45%
2019 Q4	2.2 Billion KRW	18.39%
2019 Q3	1.85 Billion KRW	-26.34%
2019 Q2	2.52 Billion KRW	43.23%
2019 Q1	1.76 Billion KRW	-87.23%
2018 FY	20.58 Billion KRW	87.77%
2018 Q2	2.51 Billion KRW	6.65%
2018 Q1	2.35 Billion KRW	-26.58%
2018 Q3	1.9 Billion KRW	-24.29%
2018 Q4	13.8 Billion KRW	624.97%
2017 Q1	2.4 Billion KRW	-25.95%
2017 FY	10.96 Billion KRW	7.24%
2017 Q4	3.21 Billion KRW	42.25%
2017 Q3	2.25 Billion KRW	-26.82%
2017 Q2	3.08 Billion KRW	28.25%
2016 FY	10.22 Billion KRW	-13.63%
2016 Q4	3.24 Billion KRW	46.53%
2016 Q3	2.21 Billion KRW	-8.48%
2016 Q2	2.42 Billion KRW	3.88%
2016 Q1	2.33 Billion KRW	0.0%
2015 FY	11.83 Billion KRW	0.0%
2013 Q3	2.27 Billion KRW	-3.06%
2013 Q2	2.34 Billion KRW	15.9%
2013 Q1	2.02 Billion KRW	5.78%
2012 FY	8.17 Billion KRW	0.0%
2012 Q4	1.91 Billion KRW	-5.98%
2012 Q3	2.03 Billion KRW	0.0%

Peer Revenue Comparison of iNtRON Biotechnology, Inc.

Name	Revenue	Revenue Difference
HLB Co., Ltd.	42.9 Billion KRW	77.657%
BINEX Co., Ltd.	154.82 Billion KRW	93.809%
Bioneer Corporation	263.23 Billion KRW	96.359%
Anterogen.Co.,Ltd.	6.5 Billion KRW	-47.463%
MEDIPOST Co., Ltd.	68.64 Billion KRW	86.036%
CrystalGenomics, Inc.	4.87 Billion KRW	-96.477%
Helixmith Co., Ltd	4.2 Billion KRW	-128.137%
Chabiotech Co.,Ltd.	953.95 Billion KRW	98.995%
Medy-Tox Inc.	221.12 Billion KRW	95.665%
Peptron, Inc.	3.34 Billion KRW	-186.827%
Amicogen, Inc.	159.9 Billion KRW	94.006%
Genexine, Inc.	4.42 Billion KRW	-116.541%
HLB Therapeutics Co.,Ltd.	53.74 Billion KRW	82.166%
LegoChem Biosciences, Inc.	34.14 Billion KRW	71.928%
ALTEOGEN Inc.	96.52 Billion KRW	90.069%
PharmaResearch Co., Ltd.	261.01 Billion KRW	96.328%
SillaJen, Inc.	3.93 Billion KRW	-143.313%
JETEMA, Co., Ltd.	58.71 Billion KRW	83.675%
OliX Pharmaceuticals,Inc	17.06 Billion KRW	43.827%
Genomictree Inc.	3.41 Billion KRW	-180.439%
MedPacto, Inc.	- KRW	-Infinity%
D&D Pharmatech	18.67 Billion KRW	48.678%
EASY BIO,Inc.	165.38 Billion KRW	94.204%
GI Innovation, Inc.	5.31 Billion KRW	-80.216%